Updating results

421 results

Sort: Relevance | Date

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Antimicrobial prescribing guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma [ID1426]

In development [GID-TA10331] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Lenalidomide for previously treated follicular lymphoma [ID1374]

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

In development [GID-TA10208] Expected publication date: TBC

Technology appraisal guidance In development

Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for untreated mantle cell lymphoma (ID1221)

In development [GID-TA10185] Expected publication date: TBC

Technology appraisal guidance In development

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Technology appraisal guidance In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

In development [GID-TA10316] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development